AIM: To determine the role of epidermal growth factor-like repeats and discoidin I-like domains 3 (EDIL3) in pathogenesis of hepatocellular carcinoma (HCC) by investigating the EDIL3 expression in HCC and its prognostic value for HCC. METHODS: EDIL3 expression was detected in 101 HCC surgical tissue samples with immunohistochemistry method, and its relation with clinicopathologic features and prognosis of HCC patients was analyzed. RESULTS: EDIL3 was highly expressed in 48.5% of the HCC patients. Although the EDIL3 expression level did not correlate with any clinicopathological parameters, Kaplan-Meier survival analysis showed that high expression level of EDIL3 resulted in a significantly poor prognosis of HCC patients (log-rank test, P = 0.010). Multivariate Cox's analysis showed that the EDIL3 expression level was a significant and independent prognostic parameter for the overall survival rate of HCC patients (hazard ratio = 1.978, 95% confidence interval = 1.139-3.435, P = 0.015). CONCLUSION: High expression level of EDIL3 predicts poor prognosis of HCC patients. EDIL3 may be a potential target of antiangiogenic therapy for HCC.
AIM: To determine the role of epidermal growth factor-like repeats and discoidin I-like domains 3 (EDIL3) in pathogenesis of hepatocellular carcinoma (HCC) by investigating the EDIL3 expression in HCC and its prognostic value for HCC. METHODS:EDIL3 expression was detected in 101 HCC surgical tissue samples with immunohistochemistry method, and its relation with clinicopathologic features and prognosis of HCC patients was analyzed. RESULTS:EDIL3 was highly expressed in 48.5% of the HCC patients. Although the EDIL3 expression level did not correlate with any clinicopathological parameters, Kaplan-Meier survival analysis showed that high expression level of EDIL3 resulted in a significantly poor prognosis of HCC patients (log-rank test, P = 0.010). Multivariate Cox's analysis showed that the EDIL3 expression level was a significant and independent prognostic parameter for the overall survival rate of HCC patients (hazard ratio = 1.978, 95% confidence interval = 1.139-3.435, P = 0.015). CONCLUSION: High expression level of EDIL3 predicts poor prognosis of HCC patients. EDIL3 may be a potential target of antiangiogenic therapy for HCC.
Authors: Sanjay Rajagopalan; Jeffrey W Olin; Stuart Young; Marlena Erikson; Paul M Grossman; Farrell O Mendelsohn; Judith G Regensteiner; William R Hiatt; Brian H Annex Journal: Hum Gene Ther Date: 2004-06 Impact factor: 5.695
Authors: C Hidai; T Zupancic; K Penta; A Mikhail; M Kawana; E E Quertermous; Y Aoka; M Fukagawa; Y Matsui; D Platika; R Auerbach; B L Hogan; R Snodgrass; T Quertermous Journal: Genes Dev Date: 1998-01-01 Impact factor: 11.361
Authors: O N El-Assal; A Yamanoi; Y Soda; M Yamaguchi; M Igarashi; A Yamamoto; T Nabika; N Nagasue Journal: Hepatology Date: 1998-06 Impact factor: 17.425
Authors: Abraham Quezada; Jeff Larson; Martha French; Rafael Ponce; Jerry Perrard; Ross Durland; Michael Coleman Journal: J Pharm Pharmacol Date: 2004-02 Impact factor: 3.765
Authors: Ji Xiao Niu; Wen Jian Zhang; Li Ya Ye; Lian Qiu Wu; Guang Jin Zhu; Zhi Hua Yang; Georges E Grau; Jin Ning Lou Journal: Eur J Cancer Prev Date: 2007-12 Impact factor: 2.497
Authors: Rui Chen; George I Mias; Jennifer Li-Pook-Than; Lihua Jiang; Hugo Y K Lam; Rong Chen; Elana Miriami; Konrad J Karczewski; Manoj Hariharan; Frederick E Dewey; Yong Cheng; Michael J Clark; Hogune Im; Lukas Habegger; Suganthi Balasubramanian; Maeve O'Huallachain; Joel T Dudley; Sara Hillenmeyer; Rajini Haraksingh; Donald Sharon; Ghia Euskirchen; Phil Lacroute; Keith Bettinger; Alan P Boyle; Maya Kasowski; Fabian Grubert; Scott Seki; Marco Garcia; Michelle Whirl-Carrillo; Mercedes Gallardo; Maria A Blasco; Peter L Greenberg; Phyllis Snyder; Teri E Klein; Russ B Altman; Atul J Butte; Euan A Ashley; Mark Gerstein; Kari C Nadeau; Hua Tang; Michael Snyder Journal: Cell Date: 2012-03-16 Impact factor: 41.582